AMBIEN (zolpidem tartrate) by Almatica Pharma is short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit containing gaba a receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation. First approved in 1992.
Drug data last refreshed 2h ago · AI intelligence enriched 4d ago
AMBIEN (zolpidem tartrate) is a short-acting sedative-hypnotic that treats insomnia by binding to benzodiazepine receptors on GABA-A channels, increasing chloride channel opening and suppressing neuronal excitation. Administered orally as a tablet, it has been a standard first-line therapy for sleep initiation since its 1992 approval. The drug is indicated for short-term insomnia treatment in adults.
LOE-approaching status signals consolidation within the brand team and potential restructuring as generic competition intensifies.
short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit containing GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized Controlled Trial of Ambient Artificial Intelligence Scribe Technologies
Health Effects of Repeated Exposure to Low Levels of Concentrated Ambient Particles in Healthy Young Volunteers
Astigmatism Correction With Intrastromal Arcuate Incisions in Eyes Undergoing Cataract Surgery With Femtosecond Laser Using the Cassini Ambient With Iris Registration (ARCUATAS)
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
Effects of Omega-3 Fatty Acids in Ambient Air Pollution Exposure in Healthy Adults
Worked on AMBIEN at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moAMBIEN roles emphasize manufacturing, technical operations, and compliance roles reflective of a mature product focused on cost optimization and supply chain efficiency rather than innovation. Career growth on this portfolio favors operations, regulatory, and finance professionals managing established commercial infrastructure.
6 open roles linked to this drug